San Francisco · Seed–Series B · 13 people tracked
Also known as BREAKOUT MANAGEMENT, LLC · Breakout Ventures /DE
Investment thesis
Breakout Ventures backs founders building companies at the frontier where science meets technology, spanning biotech, tech-bio, deep tech, hard tech, and chemistry-driven innovation. With more than a decade investing at this edge, the firm brings a team of scientists and operators with technical depth and commercial fluency to anticipate roadblocks and navigate complexity. Beyond capital, Breakout leverages a catalytic network of corporates, strategic partners, and later-stage investors to help founders gain traction, hit milestones faster, and scale into the markets they need to win.
Source: firm website, verified Aug 25, 2026.
Team · 13 people
from the firm's website & public directories
What they invest in
from 28 of 35 portfolio companiesBiotech ×22Deep Tech ×13Healthtech ×11AI & Machine Learning ×10Medical Devices ×5New Materials ×5Climate Tech ×4Hardware ×4
HQs:United States×20United Kingdom×1
Who they back
founder profiles across 17 portfolio companiesFounding team size:solo founder×72 founders×53 founders×44+ founders×1
Where their founders studiedfrom 14 founders with education data
UC San Diego ×3Harvard Medical School ×2Stanford University ×2Stanford University Graduate School of Business ×2Stanford University School of Medicine ×2
Accelerator rootsportfolio companies that came through a program
Investments · 35 tracked
founders shown can be your intro pathBy year:2026 · 12024 · 22022 · 42015 · 18 dated
Debut applies AI and biotechnology to discover and formulate cosmetic ingredients and beauty products, decoding skin and hair at the genomic level to create novel actives.
AI & Machine LearningBiotechConsumerSan Diego, US
Joshua Britton(Founder)
Co-investorsGS FuturesMaterial ImpactKdT VenturesSandbox IndustriesACVC PartnersBetter Ventures Central Llc+8 more
Twelve transforms CO2 into chemicals, fuels, and materials through carbon transformation technology.
Advanced ManufacturingCleantechClimate TechHealthtechNew MaterialsMoses Lake, US
Nicholas Flanders(Founder & CEO)inEtosha Cave(Founder)inKendra Kuhl(Founder)inAndrew Cleeland(Executive Officer, Director)Hanson Gifford(Executive Officer, Director)Henry A. Plain(Director)
Co-investorsDCVC (Data Collective)Dolby Family VenturesFifth WallAdvantage Partners Inc.Aera VCCantos Ventures+15 more
Cytovale develops microfluidic deformability cytometry technology for immune response diagnostics, with a focus on early detection and diagnosis in hospital settings.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Ajay Shah(Co-founder & CEO)inHenry Tse(Co-founder & Chief Technology Officer)inDino DiCarlo(Director, Promoter)
BoardJack Fuchs(Director, Promoter)in
Board seatLindy Fishburne· per SEC Form D
Co-investorsAlumni VenturesBasecamp FundBlackhorn VenturesBreakout LabsEMV CapitalIT-Farm Corporation+3 more
Aquaporo manufactures drinking water directly from atmospheric humidity using proprietary ALMA technology, offering residential units (Droplet) and industrial modular systems (Stream) for on-site water production.
CleantechHardwareAnaheim, US
Kyle E. Cordova(Founder)inKyle Ellis Cordova(Executive Officer, Director)
BoardKristopher H Gilman(Director)
Board seatLindy Fishburne· per SEC Form D
Co-investorsCool Climate CollectiveHumba VenturesCerberus Ventures
Checkerspot uses microalgae precision fermentation to produce specialized lipids and fats, including a bio-equivalent source of the sn-2 palmitate fat found in mother's milk, rare bioactive fatty acids, and tropical fat alternatives.
BiotechClimate TechFoodTechNew MaterialsAlameda, US
Scott Franklin(Executive Officer, Director)Charles Dimmler(Executive Officer, Director)John Krzywicki(CEO)Layla Ward(CFO)Casey Lippmeier(CTO)Leon Parker(SVP, Molecular Biology)
Board seatJulia (Thies) Moore· per SEC Form D
Co-investorsBaruch Future VenturesCavallo VenturesBuilders VCKdT VenturesRefactor Capital
Media, US
Peter Ledochowitsch(Executive Officer, Director)
Board seatLindy Fishburne· per SEC Form D · $3.5M raise · filed Jan 2022
Palo Alto, US
Bryan Mazlish(Executive Officer, Director)Jennifer Schneider(Executive Officer, Director)Ben Askew(Director)
Board seatLindy Fishburne· per SEC Form D · $16.3M raise · filed Apr 2022
STRM.BIO develops a gene therapy delivery platform based on megakaryocyte-derived extracellular vesicles (STRM MVs) that target and deliver genetic cargoes preferentially to bone marrow and hematopoietic stem cells.
BiotechDeep TechMedical Devices
Co-investorsAscension VenturesBreakout LabsDelos CapitalNYBC VenturesKdT Ventures
A-Alpha Bio uses synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions for pharmaceutical discovery and development.
AI & Machine LearningBiotechDeep TechSeattle, US
David Younger, PhD(Chief Executive Officer & Co-Founder)Randolph Lopez, PhD(Chief Technology Officer & Co-Founder)David Younger(Executive Officer, Director, Promoter)inRandolph Lopez(Founder)in
Co-investorsAngel Collective Opportunity FundFarvatn VentureLux CapitalMadrona Venture GroupBoom Capital VenturesOS Fund
Canaery (now General Sense) is developing scent-detection technology aimed at extending capabilities beyond the limits of human olfactory perception.
Deep TechHardware
Co-investors15th RockGood News VenturesDolby Family VenturesKdT Ventures
CellChorus develops a visual AI platform called TIMING that performs high-throughput dynamic analysis of single cells, measuring cell activation, killing, and movement over time for biopharmaceutical research.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesHouston, US
Dan Meyer(Founder)inNavin Varadarajan(Founder)inLaurence Cooper(Co-founder & Board Chair)Rebecca Berdeaux(Chief Scientific Officer)
Co-investorsHouston Angel NetworkTexas HALO FundY Combinator
Constellation develops foundation models of human state aimed at understanding brains, bodies, and environments.
AI & Machine LearningDeep TechHealthtech
Co-investorsMaC Venture Capital
Copernic develops catalysts for zero-carbon ammonia and e-fuels that are cost-competitive and compatible with existing industrial infrastructure.
CleantechClimate TechDeep TechEnergyCambridge, US
Aruna Ramkrishnan(Founder)inJacob Ebenstein Grose(Executive Officer, Director)
BoardLindy Fishburne(Director)inMichael Kearney(Director)inMichael LoCascio(Director)
Co-investorsFuture VenturesInnospark VenturesJuniperNew Climate VenturesThe Engine Ventures
Ecovative grows whole-cut meat alternatives and other materials from mycelium using its AirMycelium indoor cultivation platform, which integrates with existing mushroom farming infrastructure.
BiotechFoodTechNew MaterialsGreen Island, US
Gavin McIntyre(Executive Officer, Director)Eben Bayer(Executive Officer, Director)
BoardEvan Lodes(Director)Jerry Weinstein(Director)Charles Deull(Director)Jessica Harris(Director)
Co-investorsBreakout LabsStray Dog Capital
En Plus One Bio develops synthesis and manufacturing technology for RNA therapeutics, focused on producing high-purity long RNA with higher cycle efficiencies and novel chemical modifications.
BiotechDeep TechWatertown, US
Daniel Ahlstedt(Executive Officer, Director)Jonathan Rittichier(Founder)in
BoardPaxton Major(Director)inAndrew Lee(Director)inSteven Kasok(Director)
Co-investorsCoatue ManagementNorthpond Ventures
Epana Bio develops therapies for autoimmune diseases by leveraging genomics and AI to identify and target cellular origins of disease, with a focus on precision medicine for patient populations.
AI & Machine LearningBiotechDigital Health
Co-investorsBreakout LabsHAWKTAILHummingbird VenturesOMX VenturesKdT VenturesRefactor Capital
General Sense provides multi-threat detection technology that identifies explosives, narcotics, and emerging chemical threats simultaneously without specialized teams.
Deep TechDefense TechHardware
Co-investorsDraper AssociatesJuniper
Vitra develops reproductive therapies that mature eggs outside the body in a controlled environment, aiming to reduce or eliminate the hormone injections required in conventional IVF.
BiotechFemTechHealthtech
Ivana Muncie-Vasic(Founder)in
Co-investorsForeground CapitalNorth South VenturesSpacecadet VenturesBoom Capital VenturesRefactor Capital
Immusoft develops a cell therapy platform called Immune System Programming (ISP) that engineers a patient's B cells into plasma cells that produce therapeutic proteins after being infused back into the patient.
BiotechDeep TechHealthtechSeattle, US
Matthew Scholz(Founder)Sean Ainsworth(Chief Executive Officer)Robert Sikorski(Chief Medical Officer)Rob Hayes(Chief Scientific Officer)Scott McIvor(Chief Development Officer)Richard Chin, M.D.(Director)
Co-investorsBioRock VenturesBoston Harbor AngelsEQx FundInvariantes FundMichigan Capital NetworkNYBC Ventures+1 more
Modern Meadow develops animal-free, bio-fabricated leather alternatives using synthetic biology and material science for the fashion, interiors, and automotive industries.
BiotechCircular EconomyNew MaterialsPine Brook, US
Gabor Forgacs(Director, Promoter)Anna Bakst(Executive Officer, Director)Rex Liu(Executive Officer)David Williamsonin
BoardAndras Forgacs(Director, Promoter)Bart Swanson(Director)in
Co-investorsArtis VenturesAstanor VenturesBreakout LabsHorizons VenturesInventus Capital PartnersKohala Ventures+4 more
Noetik builds AI models to identify cancer patients most likely to respond to treatments and to discover new oncology drug targets.
AI & Machine LearningBiotechHealthtechSouth San Francisco, US
Jacob Rinaldi(Executive Officer, Director, Promoter)Ronald Alfa(Executive Officer, Director, Promoter)Ron Alfa, MD, PhD(Founder)in
BoardJames Hardiman(Director)inAmy Schulman(Director)in
Co-investors11.2 CapitalLinearis VenturesNorth South VenturesCatalio Capital ManagementDCVC (Data Collective)EPIC VENTURES+2 more
Quince Therapeutics is a clinical-stage biopharmaceutical company developing eDSP, an investigational therapy studied in a Phase 3 clinical trial (NEAT) for patients with Ataxia-Telangiectasia (A-T).
BiotechHealthtechWest Lafayette, US
Philip S. Low, Ph.D.(Executive Officer, Director)David Lamond(Director)Daniel Hasler(Director)Dirk Thye, M.D.(Executive Officer, Director)William J. Rutter(Director)Alex Andrianopoulos(Director)
Co-investorsElevate VenturesPfizer Venture Investments
Parallel Bio develops human immune organoids and computational tools to predict drug efficacy across diverse patient populations, replacing animal testing in drug discovery.
AI & Machine LearningBiotechDeep TechHealthtechSan Francisco, US
Robert DiFazio(Founder)inJuliana Hilliard(Founder)in
Co-investorsAIX VenturesHumba VenturesImmeasurableJulian CapitalMetaplanetSpacecadet Ventures+5 more
Passkey operates Locksmith, a computational platform that uses human genetics, biology, and pharmacology to identify synergistic drug combinations from approved and late-stage drugs, allowing existing assets to be repurposed for new indications.
AI & Machine LearningBiotechDeep Tech
Co-investorsBison VenturesWireframe Ventures
Phantom Neuro develops a minimally invasive, subcutaneous muscle-computer interface that uses under-the-skin sensors and on-device AI to translate muscle signals into control commands for robotic devices.
AI & Machine LearningBiotechMedical DevicesRoboticsAustin, US
Connor Glass(Executive Officer, Director, Promoter)in
BoardD.A. Wallach(Director)inEdward Michael(Director)inRobert Lord(Director)in
Co-investorsDraper AssociatesLionBirdTime BioVentures
Reach Industries builds frontier technologies for scientific and industrial work, starting with a visual AI copilot for laboratories.
AI & Machine LearningBiotechDeep TechRoboticsLondon, GB
Chris Beck(Founder)inSilas Adekunle(CEO)in
Co-investorsEntrepreneur FirstLunar Ventures
ShiraTronics is a medical device company developing an implantable device to treat chronic migraine disease.
BiotechHardwareHealthtechMedical DevicesBrooklyn Park, US
Robert Binney(Executive Officer, Director)
BoardJoyce Erony(Director)inZack Scott(Director)Brad Vale(Director)inCasey Tansey(Director)Mudit Jain(Executive Officer, Director)
Co-investorsAmzak HealthAPERTURE Venture PartnersGlobal BioAccess FundNorwest Venture PartnersOSF VenturesSeroba Life Sciences+3 more
Surf Bio is a preclinical biopharmaceutical company developing its SnapShot technology, which uses a proprietary polymer to create ultra-high-concentration antibody and biologic formulations (600+ mg/mL, doses over 1,000 mg) for delivery via a standard autoinjector.
BiotechDeep TechHealthtech
Co-investorsPantera Capital
A biotech company developing novel biologics designed to target and eliminate the drivers of cancer recurrence and metastasis.
Biotech
Co-investorsPfizer Venture InvestmentsTaiho Ventures, LLC
ZymoChem develops bio-based materials using proprietary Carbon Conserving (C2) microbes that convert renewable feedstocks into high-value materials with increased yields.
BiotechCircular EconomyClimate TechNew MaterialsSan Leandro, US
Harshal Chokhawala(Founder & CEO)
Co-investorsAccelr8Breakout LabsCavallo VenturesDudley FundFreshTracks CapitalPrime Partners+7 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Portfolio news
latest coverage across their companies
▶︎ CYTOVALE · funderintel.com · Jul 16, 2026
Twelve · startupsunion.com · Jul 2, 2026
AquaPoro · intelligence360.news · Jun 30, 2026
CellChorus · houston.innovationmap.com · May 18, 2026
Parallel Bio · genengnews.com · Apr 2, 2026
Immusoft · immusoft.com · Mar 30, 2026
Frequently asked questions
- How many investments has Breakout Ventures made?
- Breakout Ventures has 30 tracked investments, including 1 dated in the last 24 months.
- What stage does Breakout Ventures invest at?
- Breakout Ventures invests at the Seed, Series A, Series B stages.
- What is Breakout Ventures's typical check size?
- Breakout Ventures typically writes checks of $500K – $6M.
- What sectors does Breakout Ventures focus on?
- Breakout Ventures focuses on Biotech, Cleantech, Climate Tech, Deep Tech, Healthtech, New Materials.
- Where is Breakout Ventures located?
- Breakout Ventures is headquartered in San Francisco, US.
- Does Breakout Ventures lead rounds?
- Breakout Ventures typically participates in rounds rather than leading them.
- Who does Breakout Ventures co-invest with?
- Breakout Ventures most often shares deals with Breakout Labs, Draper Associates, Norwest Venture Partners, among 91 tracked co-investors.
Images
Co-investors · 4
SOSV is a deep tech venture capital firm that makes first-check pre-seed investments and follow-on rounds in startups focused on human and planetary health, providing lab space and hands-on support at its US locations.
Madrona Venture Group is a Seattle-founded venture firm that partners with founders across early and acceleration stages, providing capital plus hands-on support in recruiting, strategy, business development, and fundraising.
Northpond Ventures is a venture capital firm based in Bethesda, Maryland that invests in life sciences, technology, and related sectors.
Innovation Endeavors is an early-stage venture fund that invests in founders and supports venture creation through pre-team and pre-idea programs. The firm provides portfolio companies with access to mentors, advisors, and an entrepreneur ecosystem.
Firms observed investing alongside Breakout Ventures, from public investor directories. Shared companies are the overlap with Breakout Ventures's recorded portfolio.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
SOSV is a deep tech venture capital firm that makes first-check pre-seed investments and follow-on rounds in startups focused on human and planetary health, providing lab space and hands-on support at its US locations.
Giant Ventures is a venture capital firm investing in technology that transforms civilization's foundational systems across sectors including AI, energy, materials, industry, work, finance, biology and healthcare.